Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed prostate carcinoma, which has proven progression after primary hormone therapy (surgical or medicinal castration).
Patients must have increasing PSA levels (within 3 months prior to enrollment) with at least two consecutively increasing PSA levels.
PSA value before inclusion must be at least 5 ng/ml
At least 18 years of age.
At least capable of self care and up of at least 50% of waking hours (ECOG performance status 0 - 2), adequate bone marrow function and lab results.
You may not be if
Change of hormone therapy within 6 weeks prior inclusion
Prior chemotherapy
Therapy with Imatinib, or therapy with other inhibitors of tyrosinkinase.
Second neoplasm diagnosed within 5 years before study start.
Patients who require therapy with warfarin
Known diagnosis of HIV, hepatitis B, or hepatitis C infection.
Severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including severe cardiac insufficiency
Surgical therapy within 4 weeks before inclusion.
Prior therapy with isotopes strontium or rhenium.
Radiation therapy to \> 25% of bone marrow within 4 weeks before inclusion.
Treatment with other experimental substances within 30 days before study start.
Clareo Health | Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer
